首页膀胱肿瘤治疗及预后证据详情

Prognostic value of DNA methylation for bladder cancer

原文: 2018 年 发布于 BJU Int 199 卷 第 11 期 Cd012112 浏览量:188次

作者: Yu Y. Cao H. Zhang M. Shi F. Wang R. Liu X.

作者单位: Academic Urology Unit, University of Sheffield, Sheffield, UK. Electronic address: m.cumberbatch@nhs.net. Department of Urology, Medical University of Vienna, Vienna, Austria Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. Academic Urology Unit, University of Sheffield, Sheffield, UK. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Division of Urology, McGill University Health Center, Montreal, Canada. Department of Urology, Medical University of Vienna, Vienna, Austria Department of Urology, Weill Cornell Medical College, New York, NY, USA Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. EAU Guidelines Office, Brussels, Belgium. Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.3233/blc-190218

关键词: 肌层浸润性膀胱癌 保留膀胱手术 根治性膀胱切除术 Meta分析

文献简介

PURPOSE: Lymphovascular invasion (LVI) is an important step in bladder cancer cell dissemination. We aimed to perform a systematic review and meta-analysis of the literature to assess the prognostic value of LVI in radical cystectomy (RC) specimens. PATIENTS AND METHODS: A systematic review and meta-analysis of the last 10 years was performed using the MEDLINE, EMBASE, and the Cochrane libraries in July 2017. The analyses were performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. RESULTS: We retrieved 65 studies (including 78,107 patients) evaluating the effect of LVI on oncologic outcomes in patients treated with RC. LVI was reported in 35.4% of patients. LVI was associated with disease recurrence (pooled hazard ratio [HR] = 1.57; 95% CI: 1.45-1.70) and cancer-specific mortality (CSM) (pooled HR = 1.59; 95% CI: 1.48-1.73) in all studies regardless of tumor stage and node status (pT1-4 pN0-2). LVI was associated with recurrence and CSM in patients with node-negative bladder cancer (BC). In patients with node-negative BC, LVI rate increased and was associated with worse oncologic outcome. LVI had a lower but still significant association with disease recurrence and CSM in node-positive BC. CONCLUSIONS: LVI is a strong prognostic factor of worse prognosis in patients treated with RC for bladder cancer. This association is strongest in node-negative BC, but it is also in node-positive BC. LVI should be part of all pathological reporting and could provide additional information for treatment-decision making regarding adjuvant therapy after RC.

热门文献